Immunomic Therapeutics is launching an incubator and looking for one lucky startup - Baltimore


Nov. 10, 2016 12:16 pm

Immunomic Therapeutics is launching an incubator and looking for one lucky startup

Fighting cancer? This company might have some lab space for you.

Immunomic Therapeutics and JHU reps celebrate their licensing deal in November 2015.

(Photo by Stephen Babcock)

Immunomic Therapeutics signed a $315 million licensing deal with a Japanese pharmaceutical company last year.

Now the company is looking to help another Maryland biotech startup get off the ground.

The Rockville-based company is accepting applications for its Cancer Discovery Incubator through Dec. 31.


The award is offering a company a $10,000/month stipend, bench space and supplies to conduct proof-of-concept experiments. Immumonic leaders William Hearl and Teri Heiland will also provide mentorship. The company is partnering with BioHealth Innovation on the effort.

The application process includes an initial screening and pitch day, and is set to be complete by February 2017.

Immunomic developed a vaccine for allergies based on research by Johns Hopkins University professor Tom August. The company signed the licensing deal with Astellas Pharma last year, and is also looking to set its sights on cancer.

“It is exciting to pay it forward and empower a new innovator to work in Maryland and conduct proof-of-concept experiments and ultimately, attract funding, partnerships, and fuel growth,” Herl said in a statement.

Stephen Babcock

Stephen Babcock is Market Editor for Baltimore and DC. A graduate of Northeastern University, he moved to Baltimore following stints in New Orleans and Rio Arriba County, New Mexico. His work has appeared in The New York Times, Baltimore Fishbowl, NOLA Defender, Times-Picayune and the Rio Grande Sun.


Sign-up for regular updates from

Do NOT follow this link or you will be banned from the site!